-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53

Benzinga·10/12/2026 13:51:25
Listen to the news
UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.